When combined with LNP-engineered GPC3-specific CAR-NK cells, this approach elicited synergistic antitumor activity, as demonstrated by superior tumor lysis in vitro and robust tumor regression in various HCC models without systemic toxicity. The gene discussed is GPC3; the disease is neoplasm.